Cancer diagnosis & prognosis最新文献_第2页

Association of PARP1 Expression Levels and Clinical Parameters in Different Leukemic Subtypes With BCR::ABL1 p190+ Translocation. 带有 BCR::ABL1 p190+ 转位的不同白血病亚型中 PARP1 表达水平与临床参数的关系

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10368

Guilherme Passos DE Morais, Caio Bezerra Machado, Beatriz Maria Dias Nogueira, Flávia Melo Cunha DE Pinho Pessoa, Deivide DE Sousa Oliveira, Rodrigo Monteiro Ribeiro, Jean Breno Silveira DA Silva, Aline Damasceno Seabra, Fernando Augusto Rodrigues Mello Júnior, Rommel Rodriguez Burbano, André Salim Khayat, Manoel Odorico DE Moraes Filho, Maria Elisabete Amaral DE Moraes, Caroline Aquino Moreira-Nunes

{"title":"Association of PARP1 Expression Levels and Clinical Parameters in Different Leukemic Subtypes With BCR::ABL1 p190+ Translocation.","authors":"Guilherme Passos DE Morais, Caio Bezerra Machado, Beatriz Maria Dias Nogueira, Flávia Melo Cunha DE Pinho Pessoa, Deivide DE Sousa Oliveira, Rodrigo Monteiro Ribeiro, Jean Breno Silveira DA Silva, Aline Damasceno Seabra, Fernando Augusto Rodrigues Mello Júnior, Rommel Rodriguez Burbano, André Salim Khayat, Manoel Odorico DE Moraes Filho, Maria Elisabete Amaral DE Moraes, Caroline Aquino Moreira-Nunes","doi":"10.21873/cdp.10368","DOIUrl":"https://doi.org/10.21873/cdp.10368","url":null,"abstract":"Background/aim: Although the reciprocal translocation t(9;22)(q34;q11) is a hallmark of chronic myeloid leukemia (CML), it is also present in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Depending on the gene's breakpoint, it is possible to obtain three isoforms, among which p190 stands out for the poor prognosis it induces whenever it appears. Due to the genomic instability induced by BCR::ABL1, it is proposed to expand the applicability of poly-ADP-ribose polymerase-1 (PARP1) and its inhibitors in hematological neoplasms.Materials and methods: We measured the expression levels of PARP1 by quantitative real-time PCR (qPCR) using TaqMan®, correlating its expression with BCR::ABL1 p190+, to evaluate its influence in the clinic of adult patients.Results: We found that PARP1 is expressed differently in ALL, AML and CML and that p190 transcripts do not follow a linear pattern in these populations. We also found that PARP1 expression is not correlated with age, white blood cell and the amount of p190 transcripts.Conclusion: Despite the lack of statistical correlation between the variables analyzed, the role of PARP1 in BCR::ABL1 leukemia cannot be ruled out, given the instability profile promoted by this translocation. Finally, further studies involving a larger sample of patients are needed, as well as investigations into other molecular pathways that may impact on the pathogenesis of different BCR::ABL1 leukemic subtypes.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Local Recurrence Between LEN-TACE and TACE for Hepatocellular Carcinoma According to Lipiodol Accumulation. 根据脂肪碘累积情况比较 LEN-TACE 和 TACE 治疗肝细胞癌的局部复发率

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10371

Toru Ishikawa, Ryo Sato, Ryo Jimbo, Yuji Kobayashi, Toshifumi Sato, Akito Iwanaga, Tomoe Sano, Junji Yokoyama, Terasu Honma

{"title":"Comparison of Local Recurrence Between LEN-TACE and TACE for Hepatocellular Carcinoma According to Lipiodol Accumulation.","authors":"Toru Ishikawa, Ryo Sato, Ryo Jimbo, Yuji Kobayashi, Toshifumi Sato, Akito Iwanaga, Tomoe Sano, Junji Yokoyama, Terasu Honma","doi":"10.21873/cdp.10371","DOIUrl":"https://doi.org/10.21873/cdp.10371","url":null,"abstract":"Background/aim: Transarterial chemoembolization (TACE) is the standard treatment for patients with hepatocellular carcinoma in the intermediate stage; however, with advances in systemic therapy, the indications for TACE have gained significance. While lenvatinib (LEN)-TACE offers the potential for good outcomes, local recurrence has not yet been adequately investigated. Therefore, this study investigated local recurrence factors for each type of TACE, focusing on the lipiodol (Lip) value in LEN-TACE and conventional TACE.Patients and methods: Fifty patients (50 nodes) with hepatocellular carcinoma and a tumor size <7 cm who underwent LEN-TACE or TACE between January 2022 and June 2023 were included in this study to investigate local recurrence and its influencing factors.Results: The local recurrence rate after LEN-TACE was 5.6% at 6 months and 11.5% at 12 months, whereas those after TACE were 6.4% at 6 months and 13.2% at 12 months (p=0.028). There were no significant differences in local recurrence rates according to background liver factors, alpha-fetoprotein (AFP), des-γ-carboxy prothrombin (DCP) values, sex, age, and albumin-bilirubin (ALBI) score. Lipiodol (Lip) values immediately after LEN-TACE were significantly higher than those after TACE alone (p=0.021). Multivariate analysis showed that LEN-TACE had a recurrence hazard ratio of 0.184.Conclusion: LEN-TACE provided good local tumor control. Local recurrence factors included LEN pretreatment, and Lip CT values were higher immediately after LEN-TACE. Thus, LEN-TACE after upfront LEN administration may increase the effectiveness of TACE.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging Transgenic Nude Mice Expressing Spectrally-distinct Fluorescent Reporters Emitting From Blue to Far Red Light With One Instrument With Single-nanometer-tuning of Laser-excitation Fluorescence. 用一台仪器对表达从蓝光到远红光的光谱不同的荧光报告器的转基因裸鼠进行成像，并对激光激发荧光进行单纳米调谐。

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10364

Kohei Mizuta, Jose Reynoso, Sean Gallagher, April Wang, Neil Chang, Sei Morinaga, Motokazu Sato, Byung Mo Kang, Robert M Hoffman

{"title":"Imaging Transgenic Nude Mice Expressing Spectrally-distinct Fluorescent Reporters Emitting From Blue to Far Red Light With One Instrument With Single-nanometer-tuning of Laser-excitation Fluorescence.","authors":"Kohei Mizuta, Jose Reynoso, Sean Gallagher, April Wang, Neil Chang, Sei Morinaga, Motokazu Sato, Byung Mo Kang, Robert M Hoffman","doi":"10.21873/cdp.10364","DOIUrl":"https://doi.org/10.21873/cdp.10364","url":null,"abstract":"Background/aim: Transgenic nude mice expressing green fluorescent protein (GFP), red fluorescent protein (RFP), or cyan fluorescent protein (CFP) were previously developed by our laboratory, AntiCancer Inc. In the present study, we demonstrate imaging of the GFP, RFP, or CFP nude mice with single-nanometer-tuning laser fluorescence excitation with a single instrument.Materials and methods: Female transgenic C57/B6 nude GFP, RFP, and CFP mice aged six weeks were used. The images were obtained using the UVP Biospectrum Advanced system (Analytik Jena US LLC) with excitation at 480 nm and peak emission at 513 nm for GFP; 520 nm and 605 nm, respectively, for RFP; and 405 nm and 480 nm, respectively, for CFP.Results: For each color transgenic fluorescent mouse, images without background could be obtained individually with the UVP Biospectrum Advanced system.Conclusion: Using a single instrument, brilliant and well-defined images of GFP, RFP, and CFP mice were obtained with single-nanometer-tuning laser fluorescence excitation. This imaging system will be used in future studies to analyze cancer cells in the colored mice that are spectrally distinct in order to determine how stromal cells and cancer interact in the tumor microenvironment.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of Progression to Castration-resistant Prostate Cancer After Radical Prostatectomy in High-risk Prostate Cancer Patients. 高危前列腺癌患者根治性前列腺切除术后发展为阉割抗性前列腺癌的预测因素。

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10376

Takato Nishino, Shinya Yamamoto, Noboru Numao, Yoshinobu Komai, Tomohiko Oguchi, Yosuke Yasuda, Ryo Fujiwara, Takeshi Yuasa, Junji Yonese

{"title":"Predictors of Progression to Castration-resistant Prostate Cancer After Radical Prostatectomy in High-risk Prostate Cancer Patients.","authors":"Takato Nishino, Shinya Yamamoto, Noboru Numao, Yoshinobu Komai, Tomohiko Oguchi, Yosuke Yasuda, Ryo Fujiwara, Takeshi Yuasa, Junji Yonese","doi":"10.21873/cdp.10376","DOIUrl":"https://doi.org/10.21873/cdp.10376","url":null,"abstract":"Background/aim: To examine the specific time frame and identify associated risk factors from commencement of hormonal therapy to the onset of castration-resistant prostate cancer among patients who have developed biochemical recurrence following radical prostatectomy.Patients and methods: We retrospectively reviewed the records of 92 patients who developed biochemical recurrence and received hormonal therapy as initial salvage treatment after radical prostatectomy for high-risk localized prostate cancer from 2005 to 2021. The castration-resistant prostate cancer-free survival rates from the commencement of salvage hormonal therapy were analyzed using log-rank methods. Cox proportional hazard regression was performed to analyze the risk factors associated with acquiring castration resistance. The patients were stratified based on those risk factors.Results: During a median follow-up duration of 57 months, 24 (26.1%) patients developed castration-resistant prostate cancer. The 5- and 10-year castration-resistant prostate cancer-free survival rates were 73.6% and 54.5%, respectively. A multivariate analysis showed that Grade Group of 5 and prostate-specific antigen doubling time at biochemical recurrence of ≤3 months were independent predictors of castration-resistant prostate cancer. The 5-year castration-resistant prostate cancer-free survival rates in the low- and high-risk groups, stratified according to the aforementioned factors, were 85.4% and 47.6%, respectively.Conclusion: Patients in high Grade Group and short prostate-specific antigen doubling time after radical prostatectomy are more likely to develop resistance to salvage hormonal therapy.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Impact of Tumor Growth Rate During Second-line Chemotherapy in Patients With Gastric Cancer. 二线化疗期间肿瘤生长速度对胃癌患者预后的影响

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10380

Mami Yoshii, Yuichiro Miki, Hiroaki Tanaka, Tatsuro Tamura, Takahiro Toyokawa, Shigeru Lee, Kiyoshi Maeda

{"title":"Prognostic Impact of Tumor Growth Rate During Second-line Chemotherapy in Patients With Gastric Cancer.","authors":"Mami Yoshii, Yuichiro Miki, Hiroaki Tanaka, Tatsuro Tamura, Takahiro Toyokawa, Shigeru Lee, Kiyoshi Maeda","doi":"10.21873/cdp.10380","DOIUrl":"https://doi.org/10.21873/cdp.10380","url":null,"abstract":"Background/aim: Despite the remarkable developments in chemotherapy for gastric cancer (GC), rapid tumor growth is sometimes experienced during chemotherapy. This study investigated the association of tumor growth rate (TGR) during second-line chemotherapy with the prognosis of patients with GC.Patients and methods: We retrospectively reviewed 29 patients with GC treated with nab-paclitaxel plus ramucirumab as second-line chemotherapy between 2017 and 2019 at Osaka Metropolitan University. Of them, 13 cases with target lesions were classified into two groups according to TGR using a cutoff value of 0.25. Clinicopathological factors and survival outcomes were compared between the high TGR (n=5) and low TGR (n=8) groups.Results: The median duration of first-line chemotherapy was significantly longer in the high TGR group than in the low TGR group [median 298 days vs. 72.5 days, p=0.030]. Progressive disease (PD) was observed in 60% of patients with high TGR, whereas stable disease (SD) was observed in 75% patients with low TGR. The median survival time (MST) after starting chemotherapy was 488 days in the low TGR group but was not reached in the high TGR group (log rank p=0.215). The MST after PD was 145 days in the low TGR group but was not estimated in the high TGR group (log rank p=0.345).Conclusion: Based on the absence of significant differences in survival outcomes between the high and low TGR groups, sequential late-line chemotherapy might be considered important, even for patients with high TGR.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factor for Rash in Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia. 接受阿糖胞苷和依达比星诱导治疗的急性髓性白血病患者出现皮疹的风险因素

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10372

Mayako Uchida, Shigeru Ishida, Erika Mochizuki, Nana Ozawa, Hiroko Yonemitsu, Hideki Ochiai, Hanae Nakamura, Takehiro Kawashiri, Hiroyuki Watanabe, Toshikazu Tsuji, Kimitaka Suetsugu, Koji Kato, Nobuaki Egashira, Koichi Akashi, Ichiro Ieiri

{"title":"Risk Factor for Rash in Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia.","authors":"Mayako Uchida, Shigeru Ishida, Erika Mochizuki, Nana Ozawa, Hiroko Yonemitsu, Hideki Ochiai, Hanae Nakamura, Takehiro Kawashiri, Hiroyuki Watanabe, Toshikazu Tsuji, Kimitaka Suetsugu, Koji Kato, Nobuaki Egashira, Koichi Akashi, Ichiro Ieiri","doi":"10.21873/cdp.10372","DOIUrl":"https://doi.org/10.21873/cdp.10372","url":null,"abstract":"Background/aim: Rash is a common adverse event (AE) observed during cytarabine and idarubicin induction therapy in patients with acute myeloid leukemia (AML). Previous studies have highlighted the challenge in predicting the onset and duration of rash. This study aimed to determine the factors that affect the onset of rash in patients receiving induction therapy for AML.Patients and methods: This retrospective study involved 97 patients with AML who received induction chemotherapy with cytarabine and idarubicin at the Department of Hematology, Kyushu University Hospital between January 2008 and June 2022. The factors associated with rash were identified through a multivariate stepwise logistic regression analysis. Subsequently, the patient's characteristics were compared between those with risk factors and those without risk factors using a matched pair analysis.Results: Pre-existing leukopenia [odds ratio (OR)=3.294; 95% confidence interval (CI)=1.272-8.531] and good performance status (PS=0) (OR=2.717; 95%CI=1.087-6.792) were significant risk factors for rash development. Conversely, the matched pair analysis indicated that patients with pre-existing leukopenia, excluding those with a PS score of 0, exhibited a significantly (p=0.015) higher incidence of rash than those without it.Conclusion: Both multivariate logistic regression analysis and matched pair analysis identified pre-existing leukopenia as a primary risk factor for rash development associated with cytarabine and idarubicin chemotherapy.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Use of Cemiplimab in a Very Elderly Patient With Cutaneous Squamous Cell Carcinoma. 在一名皮肤鳞状细胞癌高龄患者身上成功应用塞米单抗

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10381

Elisabetta Gambale, Giulia Venturi, Adriana Guarino, Ismaela Anna Vascotto, Serena Pillozzi, Isacco Desideri, Laura Doni, Lorenzo Antonuzzo

{"title":"Successful Use of Cemiplimab in a Very Elderly Patient With Cutaneous Squamous Cell Carcinoma.","authors":"Elisabetta Gambale, Giulia Venturi, Adriana Guarino, Ismaela Anna Vascotto, Serena Pillozzi, Isacco Desideri, Laura Doni, Lorenzo Antonuzzo","doi":"10.21873/cdp.10381","DOIUrl":"https://doi.org/10.21873/cdp.10381","url":null,"abstract":"Background/aim: Cutaneous squamous cell carcinoma (SCC) is a common skin cancer with significant morbidity and mortality, particularly in advanced stages. Treatment options for metastatic cutaneous SCC in very elderly patients are limited due to concerns about treatment tolerability and potential adverse effects.Case report: We report the case of a 90-year-old female patient with metastatic cutaneous SCC who was treated with cemiplimab, a monoclonal antibody (m-Ab) against programmed cell death protein 1 (PD-1), in combination with radiotherapy. The patient received cemiplimab for a limited period, during which time she demonstrated significant clinical improvement without severe adverse events. Radiotherapy was performed as a locoregional treatment with the aim to enhance immunotherapy efficacy.Discussion: This case highlights the feasibility and effectiveness of cemiplimab in very elderly patients with metastatic cutaneous SCC. Despite the common apprehensions regarding the use of immunotherapy in this age group, our patient tolerated cemiplimab well, and the combination with radiotherapy proved beneficial. This suggests that even in very elderly patients, short-term use of cemiplimab, in conjunction with locoregional treatments such as radiotherapy, can be a viable and successful therapeutic approach.Conclusion: Cemiplimab, even in combination with radiotherapy, can be effectively and safely administered to very elderly patients with metastatic cutaneous SCC. This case supports the consideration of immunotherapy, even for a limited duration, as a practical option in the management of advanced cutaneous SCC in elderly patients, expanding the potential treatment strategies for this population.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Caspase 3 Expression Profiles in Meningioma Subtypes Based on Tissue Microarray Analysis. 基于组织芯片分析的脑膜瘤亚型中 Caspase 3 的表达特征

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10367

Dimitrios Roukas, Evangelos Tsiambas, Despoina Spyropoulou, Maria Adamopoulou, George Tsouvelas, Sofianiki Mastronikoli, Antonella-Effrosyni Monastirioti, Anastasios Kouzoupis, Andreas Lazaris, Nikolaos Kavantzas

{"title":"Caspase 3 Expression Profiles in Meningioma Subtypes Based on Tissue Microarray Analysis.","authors":"Dimitrios Roukas, Evangelos Tsiambas, Despoina Spyropoulou, Maria Adamopoulou, George Tsouvelas, Sofianiki Mastronikoli, Antonella-Effrosyni Monastirioti, Anastasios Kouzoupis, Andreas Lazaris, Nikolaos Kavantzas","doi":"10.21873/cdp.10367","DOIUrl":"https://doi.org/10.21873/cdp.10367","url":null,"abstract":"Background/aim: Concerning primary central nervous system neoplasms, meningiomas demonstrate the most common type in adults worldwide. Deregulation of apoptotic pathways in malignancies, including meningiomas, is correlated with chemoresistance and poor prognosis. Caspases represent crucial proteins that induce cell apoptosis. This study aimed to correlate caspase 3 protein expression levels to meningioma clinic-pathological features.Materials and methods: A set of fifty (n=50) meningioma lesions was included in the current analysis including a broad spectrum of histopathological subtypes (meningotheliomatous, psammomatus, transitional, fibrous, angiomatous, microcystic, atypical and anaplastic). Immunohistochemistry was implemented on tissue microarray cores of selected paraffin blocks by applying an anti-caspase 3 antibody. Additionally, an image analysis protocol was also performed in the corresponding immunostained slides.Results: Caspase 3 protein over-expression was detected in 17/50 (34%) cases, whereas the remaining 33 cases (66%) were characterized by medium to low levels of the molecule. Caspase 3 expression was statistically significantly associated with the grade of the analyzed tumors and the mitotic index (p=0.002, p=0.001, respectively). Caspase 3 expression status was also correlated with the histotype of the selected meningiomas (p=0.016).Conclusion: Caspase 3 demonstrated low expression levels in a significant subset of the examined meningiomas correlated with differentiation grade, mitotic activity, and partially with specific histotypes. Agents that could enhance caspase 3 expression - inducing its apoptotic activity - represent a very promising area in oncology for developing novel treatment regimens.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interval to Recurrence Affects Survival in Recurrent Head and Neck Squamous Cell Carcinoma. 复发间隔影响复发性头颈部鳞状细胞癌的存活率

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10378

Mioko Matsuo, Kazuki Hashimoto, Ryunosuke Kogo, Masanobu Sato, Tomomi Manako, Takashi Nakagawa

{"title":"Interval to Recurrence Affects Survival in Recurrent Head and Neck Squamous Cell Carcinoma.","authors":"Mioko Matsuo, Kazuki Hashimoto, Ryunosuke Kogo, Masanobu Sato, Tomomi Manako, Takashi Nakagawa","doi":"10.21873/cdp.10378","DOIUrl":"https://doi.org/10.21873/cdp.10378","url":null,"abstract":"Background/aim: Approximately half of head and neck squamous cell carcinoma (HNSCC) cases recur, with most recurrences occurring within the first two years after treatment. Although it has been suggested that the interval to recurrence after radical treatment is associated with prognosis in patients with HNSCC, further investigation is needed.Patients and methods: Patients diagnosed with HNSCC at Kyushu University Hospital were retrospectively analyzed (n=500). Early recurrence (ER) was defined as disease recurrence within six months of radical treatment, whereas late recurrence (LR) was defined as recurrence after more than six months. Continuous variables were assessed using the Mann-Whitney U-test and categorical variables were assessed using Fisher's exact test.Results: A total of 234 patients experienced recurrence, with 110 and 124 patients experiencing ER (recurrence within two to six months) and LR (recurrence after six months), respectively. Multivariate analyses identified two independent risk factors for poor prognosis: ER [hazard ratio (HR)=3.200, 95% confidence interval (CI)=1.570-6.521, p=0.001] and absence of radiotherapy (HR=0.374, 95%CI=0.191-0.733, p=0.004). In patients with recurrent HNSCC, a short interval to recurrence is a risk factor for poor prognosis and survival. This study demonstrated the prognostic value of ER in these patients.Conclusion: The selection of treatment for patients with recurrent head and neck squamous cell carcinoma should consider the timing of recurrence, the initial treatment regimen, and the strategy for changing salvage therapy depending on the recurrence status.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictive Value of the Prostate-specific Antigen Doubling Time for the Effectiveness of Metastasis-directed Radiotherapy in Patients With Oligometastases After Radical Treatment for Non-metastatic Prostate Cancer. 前列腺特异性抗原倍增时间对非转移性前列腺癌根治术后寡转移灶患者转移导向放疗效果的预测价值

Cancer diagnosis & prognosis Pub Date : 2024-09-01 DOI: 10.21873/cdp.10375

Dai Koguchi, Ken-Ichi Tabata, Shuhei Hirano, Soichiro Shimura, Takefumi Satoh, Masaomi Ikeda, Kazumasa Matsumoto, Yuzuru Niibe, Masatsugu Iwamura

{"title":"Predictive Value of the Prostate-specific Antigen Doubling Time for the Effectiveness of Metastasis-directed Radiotherapy in Patients With Oligometastases After Radical Treatment for Non-metastatic Prostate Cancer.","authors":"Dai Koguchi, Ken-Ichi Tabata, Shuhei Hirano, Soichiro Shimura, Takefumi Satoh, Masaomi Ikeda, Kazumasa Matsumoto, Yuzuru Niibe, Masatsugu Iwamura","doi":"10.21873/cdp.10375","DOIUrl":"https://doi.org/10.21873/cdp.10375","url":null,"abstract":"Background/aim: Data on metastasis-directed radiotherapy (MDRT) are limited, particularly regarding its association with the prostate-specific antigen (PSA) doubling time (PSADT). The present study evaluated the oncological outcomes of MDRT on the basis of the PSADT in oligo-recurrent prostate cancer patients.Patients and methods: We retrospectively reviewed clinical data of 35 MDRTs for 29 patients at the Kitasato University Hospital, targeting oligometastatic prostate cancer developed after radical treatment for non-metastatic prostate cancer. Thirty-five MDRTs were classified into the PSADT >3 months (n=25) or PSADT ≤3 months group (n=10). Statistical analyses were performed to compare associations between the two PSADT groups and oncological outcomes such as progression-free survival (PFS) and PSA response after MDRT.Results: There were no significant differences between the two groups in terms of the clinicopathological features. Kaplan-Meier analysis showed that PFS was significantly better in the PSADT >3 months group than in the PSADT ≤3 months group [median: 13.3 versus (vs.) 2.6 months, p=0.046]. Regarding castration sensitivity, the predictive role of PSADT >3 months was maintained in 21 patients who received MDRT without prior salvage hormone therapy (median PFS: 12.7 vs. 2.6 months, p=0.024). In the castration-resistant setting (n=14), the frequency of a decrease in serum PSA levels after MDRT by 90% was 54.5% (median PFS: 23.1 months).Conclusion: MDRT can provide benefit especially for patients with PSADT ≥3 months who had oligo-recurrence after the radical treatment for non-metastatic prostate cancer.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0